Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Role of FLT3 Inhibitors in Chemo-Ineligible AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

February 1st 2021

MRD Monitoring in FLT3 ITD AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 25th 2021

Assessing MRD Status in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 25th 2021

Prognostic Significance of IDH Mutations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 21st 2021

FLT3 Testing for Treatment of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 21st 2021

Molecular Testing in Community Practices

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 15th 2021

Role of Molecular Testing in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

January 15th 2021

Treating Chronic Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Graft-vs-Host Disease Prophylaxis Clinical Trials

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Special Transplant Situations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Risk Factors for Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Overview of Graft-Vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Members of the Transplant Team

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Timing of Referral for Transplant

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Clinical Trial Investigation: Where to Go From Here

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Future of GvHD: Promising Agents in Development

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GvHD Management Recommendations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

REACH2 Trial: Practical Implications and AE Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Treatment for Steroid-Refractory GVHD: REACH2

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

When to Initiate Second-Line Therapy

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Second-Line Therapy for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Role of Steroids in GvHD Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Multidisciplinary Treatment and Supportive Care

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Importance of Multidisciplinary Approach

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Frontline Agents for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GVHD Grading and Staging

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Risk Factors, Incidence & Typical Presentation of GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Nature of Acute and Chronic GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Articles by Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Role of FLT3 Inhibitors in Chemo-Ineligible AML

MRD Monitoring in FLT3 ITD AML

Assessing MRD Status in AML

Prognostic Significance of IDH Mutations in AML

FLT3 Testing for Treatment of AML

Molecular Testing in Community Practices

Role of Molecular Testing in AML

Treating Chronic Graft-vs-Host Disease

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

Graft-vs-Host Disease Prophylaxis Clinical Trials

Special Transplant Situations

Risk Factors for Graft-vs-Host Disease

Overview of Graft-Vs-Host Disease

Members of the Transplant Team

Timing of Referral for Transplant

Clinical Trial Investigation: Where to Go From Here

The Future of GvHD: Promising Agents in Development

GvHD Management Recommendations

REACH2 Trial: Practical Implications and AE Management

Treatment for Steroid-Refractory GVHD: REACH2

When to Initiate Second-Line Therapy

Second-Line Therapy for GvHD

The Role of Steroids in GvHD Management

Multidisciplinary Treatment and Supportive Care

The Importance of Multidisciplinary Approach

Frontline Agents for GvHD

GVHD Grading and Staging

Risk Factors, Incidence & Typical Presentation of GvHD

The Nature of Acute and Chronic GvHD

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma